Stage IVA Oropharyngeal Squamous Cell Carcinoma Recruiting Phase 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0039579 (Stage IVA Oropharyngeal Squamous Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02827838Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx CancerTreatment